Home » Chinese Healthcare Investors »


|| Chinese Hepalink acquired US Cytovance Biologics for $205 million

hepacyto.jpgShenzhen Hepalink, a Chinese provider of material to global pharma firms, has acquired Cytovance Biologics, a US Oklahoma City bio-pharma manufacturing firm, for $205 million

Established in 2003 and based in US Oklahoma City, Cytovance Biologics is a biopharmaceutical contract manufacturing company, specializing in the production of therapeutic proteins and antibodies. Established in 1998 and listed on the Shenzhen Stock Exchange, Hepalink is a provider of Heparin Sodium API to pharmaceutical companies, such as Sanofi-Aventis, Fresenius -Kabi and Novartis.

To see a list of investors from China similar to Shenzhen Hepalink, check the Chinese Investors Directory.

More details follows:



Previous Post: China JD Capital acquired Ageas Hong Kong business for $1.4 billion
Next Post: Chinese private equity firm Tairui acquired stake at Canadian Western Potash for $80 million




|About Us

SinaBeat Rubenstein
SinaBeat.com provides insight, analysis and research on private investors from China since 2012.

We cover Private Equity, Venture Capital, Real Estate and Institutional Investors from China, Hong Kong and Macau.

Our Chinese Investors Directory can be used as a reliable source on information about investors from China.



|Subscribe to mailing list

Enter your email address:



Careers  |  Sponsorship |  Sitemap |  Terms  |  Privacy Policy

Copyright 2007 - 2018     SinaBeat.com

Follow us: RSS  |   SinaBeat on Twitter  |   SinaBeat on Facebook  |   SinaBeat on Google+  |   SinaBeat on LinkedIn